Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden.

Overview

1. Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli,Naples, Italy
2. Department of Brain Sciences, Imperial College London,London, UK
3. Academic Neurology, Academic Unit of Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham,Nottingham, UK
4. Department of Neurology, Nottingham University Hospitals NHS Trust,Nottingham, UK
5. Institute for Life Sciences, Swansea University,Swansea, UK
6. Centre for Inflammatory Disease Monash Health, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University,Melbourne, Australia
7. Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University,Cardiff, Wales UK
8. Department of Neurology, University Hospital of Wales,Cardiff, Wales UK
9. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology,London, UK
10. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona,Verona, Italy

Abstract

Determinants of long-term disability in multiple sclerosis (MS) remain incompletely understood, with clinical course varying greatly among individuals. Recent integrative genetic models have identified genomic clusters associated with divergent disability trajectories. Here, we integrated clinical, genetic, and postmortem neuropathological data from 291 MS brain donors from the UK MS Society Tissue Bank to test whether genomic severity clusters converge on distinct tissue phenotypes. Consistent with prior stratification, donors in genomic cluster 2 had lower age-adjusted disease duration score (ADDS) than cluster 3 (β = − 0.195, P = 0.023) and a shorter interval from progression to death than cluster 1 (β = − 0.225, P = 0.049). However, this adverse clinical profile did not reflect greater active or chronic active lesion burden. Instead, chronic active broad-rim lesions were more frequent in cluster 1 than clusters 2 and 3 (37.3% vs 24.0% and 27.2%; both FDR = 0.043), whereas chronic inactive lesions were enriched in clusters 2 and 3 relative to cluster 1 (58.2% vs 70.0% and 73.8%; FDR = 0.154 and 0.030, respectively). This dissociation was strongly influenced by HLA genetic background: cluster 1 carried the highest HLA genetic burden, which was associated with greater non-lesional HLA-D immunoreactivity (rho = 0.48, FDR < 0.001), higher HLA-DRB1 (rho = 0.514, FDR < 0.001) and HLA-DRB5 (rho = 0.740, FDR < 0.001) mRNA expression, more active lesions (rho = 0.21, FDR = 0.007) and chronic active broad-rim lesions (rho = 0.19, FDR = 0.017), and fewer chronic inactive lesions (rho = − 0.26, FDR < 0.001), but not with clinical severity. Although chronic active lesion burden remained a strong tissue correlate of severity, adjustment for it strengthened the association between cluster 2 and worse outcome (ADDS: cluster 2 vs 1: β = − 0.216, Holm-adjusted P = 0.038; cluster 2 vs 3: β = − 0.246, Holm-adjusted P = 0.012; time from progression to death: cluster 2 vs 1: β = − 0.288, Holm-adjusted P = 0.049). Overall, these findings indicate that (i) HLA genetic background shapes the neuropathological representation of inflammatory lesions, and (ii) the adverse clinical profile of cluster 2 is not fully explained by HLA-D-defined chronic active lesion burden in the sampled postmortem tissue, suggesting that genomic severity clusters and chronic active lesion burden capture complementary aspects of MS progression.

Supplementary Information: The online version contains supplementary material available at 10.1007/s00401-026-03062-x.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Data availability

The data and code that support the findings of this study are available from the corresponding author upon reasonable request and subject to approval by the relevant data custodians and governance procedures.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

• Publisher: n/a → Springer Science+Business Media

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 18 authors, 6 keywords, 10 MeSH terms, 1 funder, 25 references.

Cite

This paper

Abbadessa, G., Kreft, K. L., Howell, O., de Oliveira, J. V. C., Cooze, B., Papadaki, A., Jacinto, J. M., Farkas, I., Leung, Y.-Y., Bonavita, S., Tallantyre, E. C., Robertson, N. P., Nagano, A., Rizig, M., Magliozzi, R., Owen, D., Reynolds, R., & Nicholas, R. (2026). Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. Acta neuropathologica, 152(1), 24. https://doi.org/10.1007/s00401-026-03062-x

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41586-026-10310-3 [code]

DNA damage burden causes selective CUX2 neuron loss in neuroinflammation.

Journal: Nature

In common: multiple sclerosis, cellular / molecular, 3 references

[2] doi:10.3389/fbinf.2026.1832826 [code]

Spatial transcriptomics reveal heterogeneous cell‒cell interactions among brain regions in cuprizone model consistent with multiple sclerosis lesions.

Journal: Frontiers in bioinformatics

In common: multiple sclerosis, cellular / molecular, 3 references

[3] doi:10.1162/imag.a.1251

Detection of slowly expanding lesions in people with multiple sclerosis using MRI: A scoping review.

Journal: Imaging neuroscience (Cambridge, Mass.)

In common: multiple sclerosis, 2 references

[4] doi:10.1002/acn3.70458 [code]

The Multiple Sclerosis Severity Allele rs10191329&lt;sup&gt;A&lt;/sup&gt; and Cognitive Function: A UK Biobank Study.

Journal: Annals of clinical and translational neurology

In common: multiple sclerosis, 2 references

[5] doi:10.1186/s12974-026-03895-z [code]

Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.

Journal: Journal of neuroinflammation

In common: multiple sclerosis, cellular / molecular, 2 references

[6] doi:10.3389/fimmu.2026.1805464

Chronic low-grade inflammation, genetic susceptibility, and the risk of multiple sclerosis: a prospective cohort study.

Journal: Frontiers in immunology

In common: multiple sclerosis, 2 references

[7] doi:10.1016/j.isci.2026.115744

Multiple sclerosis-associated HLA demarcates EBV-specific CD8&lt;sup&gt;+&lt;/sup&gt; T cells with an exhausted and brain residency phenotype.

Journal: iScience

In common: multiple sclerosis, 2 references

[8] doi:10.1016/j.ebiom.2026.106261 [code]

Genome-wide association studies of brain diffusion kurtosis imaging phenotypes.

Journal: EBioMedicine

In common: 2 references

[9] doi:10.3348/kjr.2026.0103 [code]

Deep Learning-Based Automated Detection and Burden Assessment of Paramagnetic Rim Lesions on Quantitative Susceptibility Mapping in Patients With Multiple Sclerosis.

Journal: Korean journal of radiology

In common: multiple sclerosis, 1 reference

[10] doi:10.3390/ijms27167275 [code]

Integrative Multi-Omics Analysis of Multiple Sclerosis Reveals Cell-Type-Specific Regulatory Landscapes and Discordant Methylation-Expression Coupling.

Journal: International journal of molecular sciences

In common: multiple sclerosis, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.